ArriVent BioPharma, Inc. Common StockAVBPNASDAQ
LOADING
|||
Cash Flow Under Pressure
Trending lower, below historical average, strong compound growth.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$-70.21M
↓ 54% below average
Average (3y)
$-45.57M
Historical baseline
Range
High:$-12.59M
Low:$-70.21M
CAGR
+77.3%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $-70.21M | -25.7% |
| 2023 | $-55.84M | -28.0% |
| 2022 | $-43.63M | -246.6% |
| 2021 | $-12.59M | - |